Pre-clinical medical device company Microbot Medical has received funding worth NIS1.62m ($440,000) from the Israel Innovation Authority (IIA) for its endovascular surgical robotic system LIBERTY.

The grant will enable the company to further develop its manufacturing process related to the LIBERTY Robotic Surgical System.

Microbot stated that this is the first time it has secured approval for a grant for the “transition from development to manufacturing” programme.

Microbot CEO Harel Gadot said: “This non-dilutive grant will facilitate our efforts to establish the manufacturing infrastructure capability for the LIBERTY system.

“While we will work with manufacturing partners to scale production, the sophisticated and crucial core technology and elements of the manufacturing process are expected to be handled internally.

“The grant will help us further establish certain advanced manufacturing capabilities in-house to assure the highest quality, efficiency and reliability by reducing logistical barriers and maintaining a competitive advantage.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The LIBERTY Robotic Surgical System is being developed for use in endovascular procedures to avoid costly equipment besides lowering radiation exposure and the workload of physicians.

It is the first ever single-use endovascular surgical robotic system designed to improve endovascular procedures.

Last month, the robotic surgical system completed more than 100th catheterisations during multiple pre-clinical studies. The system achieved a success rate of 95% in meeting pre-determined vascular targets.

In regards to the IIA grant, Microbot is also required to pay royalties ranging from 3% to 5% of its future sales of the LIBERTY product as well as interest.